A European SaaS company, established in late 2020, is available for sale at a valuation of $1,050,000. The company specializes in monitoring online pharmaceutical pricing across several countries. Since its inception, it has secured 20 enterprise clients, including major pharmaceutical and cosmetic corporations. It operates with minimal input—requiring only a part-time commitment from the owner, as processes are nearly fully automated. In recent years, the company's revenue has grown significantly, reaching $307,400 in 2023 with a net profit of $239,600. Despite its success, the founder, who initially started the company as a learning project without specific business goals, is looking to pursue other interests and thus, wishes to sell to a motivated buyer who can unlock the business's unexplored potential. The business presents growth opportunities such as expanding sales in monitored markets, venturing into new geographical areas, introducing a lower-tier product, and branching into other sectors like technology or cosmetics. The ideal buyer could be a consultancy firm, an investment entity, or a company in e-commerce aiming to diversify into pharmaceuticals. The sale includes all domains, proprietary software, customer contracts, and data needed to operate the business. The founder will provide post-sale support to ensure a smooth transition. The business is sold as a turnkey operation with no licenses required; no legal issues are pending nor any trademark risks present. The transaction, preferably in Bitcoin, will be treated as an asset sale.